- Home
- LH vs INCY Comparison
LH vs INCY Comparison
Compare LH & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LH | INCY |
|---|---|---|
| Founded | 1971 | 1991 |
| Country | United States | United States |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 24.5B |
| IPO Year | 2005 | 1994 |
Fundamental Metrics
Financial Performance| Metric | LH | INCY |
|---|---|---|
| Price | $370.33 | $121.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 28 |
| Target Price | ★ $390.06 | $131.50 |
| AVG Volume (30 Days) | 729.7K | ★ 1.7M |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | 18.33 | ★ 4173.33 |
| EPS | ★ 10.22 | 0.50 |
| Revenue | ★ $13,951,700,000.00 | $3,394,635,000.00 |
| Revenue This Year | $6.24 | $17.74 |
| Revenue Next Year | $5.37 | $4.22 |
| P/E Ratio | ★ $36.30 | $243.91 |
| Revenue Growth | 7.25 | ★ 13.67 |
| 52 Week Low | $245.00 | $89.25 |
| 52 Week High | $375.10 | $132.60 |
Technical Indicators
Market Signals| Indicator | LH | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 69.97 | 54.90 |
| Support Level | $256.51 | $120.79 |
| Resistance Level | $371.00 | $130.53 |
| Average True Range (ATR) | 11.05 | 4.17 |
| MACD | 1.00 | 0.60 |
| Stochastic Oscillator | 91.13 | 79.42 |
Price Performance
Historical ComparisonAbout LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.